MicroPort Scientific Corporation (HKG:853): Is Breakeven Near?

MicroPort Scientific Corporation (HKG:853) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People’s Republic of China, Europe, Middle East and Africa, Japan, and internationally. The HK$24b market-cap company announced a latest loss of US$214m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on MicroPort Scientific's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Consensus from 6 of the Hong Kong Medical Equipment analysts is that MicroPort Scientific is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of US$36m in 2026. So, the company is predicted to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 101% year-on-year, on average, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving MicroPort Scientific's growth isn’t the focus of this broad overview, though, take into account that typically a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

See our latest analysis for MicroPort Scientific

One thing we would like to bring into light with MicroPort Scientific is its debt-to-equity ratio of 140%. Typically, debt shouldn’t exceed 40% of your equity, which in this case, the company has significantly overshot. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.

Next Steps:

There are too many aspects of MicroPort Scientific to cover in one brief article, but the key fundamentals for the company can all be found in one place – MicroPort Scientific's company page on Simply Wall St. We've also put together a list of pertinent aspects you should look at:

1. Valuation: What is MicroPort Scientific worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether MicroPort Scientific is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on MicroPort Scientific’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.